Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo

Patient Pati Pyana, Modou Sere, Jacques Kaboré, Thierry De Meeûs, Annette MacLeod, Bruno Bucheton, Nick Van Reet, Philippe Büscher, Adrien Marie Belem, Vincent Jamonneau

    Research output: Contribution to journalA1: Web of Science-article

    Abstract

    Human African trypanosomiasis (HAT) in the Democratic Republic of the Congo (DRC) is caused by the protozoan Trypanosoma brucei gambiense. Until recently, all patients in the second or neurological stage of the disease were treated with melarsoprol. At the end of the past and the beginning of the present century, alarmingly high relapse rates in patients treated with melarsoprol were reported in isolated HAT foci. In the Mbuji-Mayi focus of DRC, a particular mutation that confers cross resistance for pentamidine and melarsoprol was recently found for all strains studied. Nevertheless, treatment successfully cured a significant proportion of patients. To check for the existence of other possible genetic factors of the parasites, we genotyped trypanosomes isolated from patients before and after treatment (relapsing patients) with eight microsatellite markers. We found no evidence of any genetic correlation between parasite genotype and treatment outcome and we concluded that relapse or cure probably depend more on patients' factors such as disease progression, nutritional or immunological status or co-infections with other pathogens. The existence of a melarsoprol and pentamidine resistance associated mutation at such high rates highlights an increasing problem, even for other drugs, especially those using the same transporters as melarsoprol and pentamidine.

    Original languageEnglish
    JournalInfection, Genetics and Evolution
    Volume30
    Pages (from-to)128-133
    Number of pages6
    ISSN1567-1348
    DOIs
    Publication statusPublished - 2015

    Keywords

    • B510-infections
    • human African trypanosomiasis
    • melarsoprol
    • resistance
    • Trypanosoma brucei gambiense

    Fingerprint

    Dive into the research topics of 'Population genetics of <i>Trypanosoma brucei gambiense</i> in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo'. Together they form a unique fingerprint.

    Cite this